Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Citius OncologyCTOR +9.01%10 Cash-to-Debt is 1.62 as of Jun. 2026, which is 22% above its 10-year median of 1.33. GuruFocus rates CTOR with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 982 Drug Manufacturers companies, Citius Oncology ranks better than 57.23% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Citius Oncology's cash to debt ratio for the quarter that ended in Jun. 2026 was 1.62.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Citius Oncologycould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Citius Oncology's Cash-to-Debt or its related term are showing as below:
CTOR'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.69 Med: 1.33 Max: 1.92
Current: 1.62
During the past 4 years, Citius Oncology's highest Cash to Debt Ratio was 1.92. The lowest was 0.69. And the median was 1.33.
CTOR's Cash-to-Debt is ranked better than 57.23% of 982
companies
in the Drug Manufacturers industry
Industry Median: 0.97
vs CTOR: 1.62
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Citius Oncology Cash-to-Debt Related Terms
Citius Oncology Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Citius Oncology's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Citius Oncology's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Citius Oncology Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Citius Oncology's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Citius Oncology's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Citius Oncology (CTOR) has a Cash-to-Debt of 1.62 as of Jun. 2026. This is 22% above median its historical median of 1.33. Over the past decade, Citius Oncology's Cash-to-Debt has ranged from 0.69 to 1.92. According to the industry distribution chart, Citius Oncology ranks #420 out of 982 companies in the Drug Manufacturers industry, placing it in the top 42.8%.
Is Citius Oncology's Cash-to-Debt too high?
Citius Oncology's current Cash-to-Debt of 1.62 is 22% above median its 10-year median of 1.33. Over the past 10 years, this metric has ranged from a low of 0.69 to a high of 1.92. The Drug Manufacturers industry median Cash-to-Debt is 0.97. Citius Oncology's value of 1.62 is 67% above this industry median. Based on the distribution chart, Citius Oncology ranks #420 out of 982 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Citius Oncology has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Citius Oncology's Cash-to-Debt compare to ZYBT and INCR?
According to the Drug Manufacturers industry distribution chart, Citius Oncology ranks #420 out of 982 companies for Cash-to-Debt. This puts Citius Oncology in the upper half of its industry. The industry median Cash-to-Debt is 0.97. Citius Oncology's value of 1.62 is 67% above this benchmark. Historically, Citius Oncology's own Cash-to-Debt has ranged from 0.69 to 1.92 over the past decade. While the company's 10-year median is 1.33 vs. the industry median of 0.97, Citius Oncology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 0.97, based on 982 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Citius Oncology's current Cash-to-Debt of 1.62 is 67% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 0.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Citius Oncology's current Cash-to-Debt is 1.62, which is 22% above median its own 10-year median of 1.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citius Oncology stock overvalued right now?
Citius Oncology (CTOR) has a current Cash-to-Debt of 1.62. The current Cash-to-Debt is 1.62, which is 22% above median its 10-year median of 1.33 and 67% above the Drug Manufacturers industry median of 0.97. Citius Oncology's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Citius Oncology (CTOR), the current Cash-to-Debt is 1.62 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
10GF Score
Get the complete analysis for CTOR
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTOR has been successfully added to your 
